Niemann-Pick Disease
September 13, 2011
E.R. physician Dr. Travis Stork explains how Niemann-Pick disease affects the body.
TRND Research Leads to NIH Trial to Test Drug for Niemann-Pick Type C1
Today, a promising new treatment is on the horizon. On Jan. 23, 2013, NIH initiated a Phase I clinical trial to evaluate the safety and effectiveness of cyclodextrin as a potential therapy for Niemann-Pick type C1.
This progress is the result of the collaborative efforts of an award-winning, multidisciplinary team of experts from NCATS, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Human Genome Research Institute; Janssen Research & Development, LLC; Washington University in St. Louis School of Medicine; Albert Einstein School of Medicine, New York City; and University of Pennsylvania, Philadelphia.
Niemann-Pick Disease Type C (NPC) – Epidemiology Forecast to 2027
Report Scope:
The report covers detailed overview of Niemann-Pick Disease Type C (NPC) explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan The Report assesses the disease risk and burden and highlights the unmet needs of Niemann-Pick Disease Type C (NPC) The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population The report provides the segmentation of the disease epidemiology by total prevalent patient population, diagnosed population, sub-types and clinical distribution in 7MM